Literature DB >> 11872280

Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center.

Michael P Mac Manus1, Kevin Wong, Rodney J Hicks, Jane P Matthews, Andrew Wirth, David L Ball.   

Abstract

PURPOSE: At our center, approximately 30% of radical radiotherapy (RRT) candidates become ineligible for RRT for non-small-cell lung cancer (NSCLC) after positron emission tomography (PET). We hypothesized that early cancer death rates would be lower in patients receiving RRT after PET staging compared with conventionally staged patients. METHODS AND MATERIALS: Two prospective cohorts were compared. Cohort 1 consisted of all participants in an Australian randomized trial from our center given 60 Gy conventionally fractionated RRT with or without concurrent carboplatin from 1989 to 1995. Eligible patients had Stage I--III, Eastern Cooperative Oncology Group status 0 or 1, <10% weight loss, and had not undergone PET. Cohort 2 included all RRT candidates between November 1996 and April 1999 who received RRT after PET staging and fulfilled the above criteria for stage, Eastern Cooperative Oncology Group status, and weight loss.
RESULTS: Eighty and 77 eligible patients comprised the PET and non-PET groups, respectively. The PET-selected patients had significantly less weight loss; 73% and 49% of the PET and non-PET patients, respectively, received chemotherapy. The median survival was 31 months for PET patients and 16 months for non-PET patients. Mortality from NSCLC and other causes in the first year was 17% and 8% for PET patients and 32% and 4% for non-PET patients, respectively. The hazard ratio for NSCLC mortality for PET vs. non-PET patients was 0.49 (p = 0.0016) on unifactorial analysis and was 0.55 (p = 0.0075) after adjusting for chemotherapy, which significantly improved survival.
CONCLUSION: Patients selected for RRT after PET have lower early cancer mortality than those selected using conventional imaging.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872280     DOI: 10.1016/s0360-3016(01)02673-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Lung cancer 5: state of the art radiotherapy for lung cancer.

Authors:  A Price
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  PET/CT: a new imaging technology in nuclear medicine.

Authors:  Heiko Schöder; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-05       Impact factor: 9.236

3.  PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancer.

Authors:  Sukran Ulger; Nilgun Yilmaz Demirci; Ercan Aydinkarahaliloglu; Fatih Caglar Kahraman; Ozlem Ozmen; Yurdanur Erdogan; Eren Cetin; Emine Avci; Mustafa Cengiz
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

4.  Do multidisciplinary meetings follow guideline-based care?

Authors:  Shalini K Vinod; Mark A Sidhom; Geoff P Delaney
Journal:  J Oncol Pract       Date:  2010-11       Impact factor: 3.840

5.  Conventional 3D staging PET/CT in CT simulation for lung cancer: impact of rigid and deformable target volume alignments for radiotherapy treatment planning.

Authors:  G G Hanna; J R Van Sörnsen De Koste; K J Carson; J M O'Sullivan; A R Hounsell; S Senan
Journal:  Br J Radiol       Date:  2011-01-11       Impact factor: 3.039

6.  ICORG 06-35: a prospective evaluation of PET-CT scan in patients with non-operable or non-resectable non-small cell lung cancer treated by radical 3-dimensional conformal radiation therapy: a phase II study.

Authors:  Karla A Lee; Guhan Rangaswamy; Naomi A Lavan; Mary Dunne; Conor D Collins; Cormac Small; Pierre Thirion
Journal:  Ir J Med Sci       Date:  2019-05-06       Impact factor: 1.568

Review 7.  Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization.

Authors:  Michael MacManus; Sarah Everitt; Tanja Schimek-Jasch; X Allen Li; Ursula Nestle; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2017-12

8.  Incorporating PET information in radiation therapy planning.

Authors:  M Macmanus; T Leong
Journal:  Biomed Imaging Interv J       Date:  2007-01-01

9.  Conformal radiotherapy and molecular imaging: complementary technologies in cancer therapy.

Authors:  Mp Mac Manus
Journal:  Biomed Imaging Interv J       Date:  2006-01-01

10.  Radiotherapy Planning and Molecular Imaging in Lung Cancer.

Authors:  Angelina Filice; Massimiliano Casali; Patrizia Ciammella; Marco Galaverni; Federica Fioroni; Cinzia Iotti; Annibale Versari
Journal:  Curr Radiopharm       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.